- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| LOTUS PHARMACEUTICALS Aktie jetzt für 0€ handeln |
0 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| STADA ARZNEIMITTEL | - | - | PRESSESPIEGEL/Unternehmen: SAP, BOSCH, CONDOR/LUFTHANSA, BAYWA, ELI LILLY, KKR, STADA, JPMORGAN CHASE | DJ PRESSESPIEGEL/Unternehmen
Die wirtschaftsrelevanten Themen aus den Medien, zusammengestellt von Dow Jones Newswires.
SAP - Der Softwarekonzern SAP hat vor dem Einheitlichen Patentgericht... ► Artikel lesen | |
| IONIS PHARMACEUTICALS | 36,650 | +3,33 % | Ionis Pharmaceuticals: Spannender Ausblick | Das US-Biotechunternehmen Ionis Pharmaceuticals durchläuft derzeit eine hochspannende Phase. Ionis gilt als Pionier auf dem Gebiet der Antisense-Oligonukleotid-(ASO)-Technologie. In der Fachzeitschrift... ► Artikel lesen | |
| CSPC PHARMA | 1,186 | +9,16 % | CSPC PHARMA (01093): DATE OF BOARD MEETING | ||
| SELLAS LIFE SCIENCES | 1,344 | -2,33 % | SELLAS Life Sciences Group, Inc.: SELLAS Life Sciences Announces Independent Data Monitoring Committee Periodic Review and Positive Recommendation to Continue Pivotal Phase 3 REGAL Trial of GPS in AML Without Modification | - Final Analysis Anticipated by Year-End Upon Occurrence of 80 Events - NEW YORK, Aug. 07, 2025 (GLOBE NEWSWIRE) -- SELLAS Life Sciences Group, Inc. (NASDAQ: SLS) ("SELLAS'' or the... ► Artikel lesen | |
| ACADIA PHARMACEUTICALS | 22,010 | +0,96 % | Acadia Pharmaceuticals: Wachstumsstrategie und Innovationen im Fokus der Anleger | ||
| MADRIGAL PHARMACEUTICALS | 319,10 | +3,84 % | Piper Sandler reiterates Overweight rating on Madrigal stock amid strong launch | ||
| CATALYST PHARMACEUTICALS | 17,395 | -0,14 % | Catalyst Pharmaceuticals reaffirms $545M-$565M 2025 revenue guidance while accelerating FIRDAPSE oncology expansion | ||
| METRIOPHARM | - | - | MetrioPharm gains orphan drug status from EMA for MP1032 | ||
| ENZON PHARMACEUTICALS | 0,046 | +1,10 % | Enzon Pharmaceuticals, Inc: Enzon and Viskase Enter into Merger Agreement | CRANFORD, N.J. and LOMBARD, Ill., June 20, 2025 (GLOBE NEWSWIRE) -- Enzon Pharmaceuticals, Inc. (OTCQX: ENZN) ("Enzon" or the "Company") and Viskase Companies, Inc. (OTC Pink Limited: VKSC) ("Viskase")... ► Artikel lesen | |
| OPUS GENETICS | 0,911 | -4,71 % | Opus Genetics, Inc.: Opus Genetics Announces Financial Results for Second Quarter 2025 and Provides Corporate Update | ||
| ELITE PHARMACEUTICALS | - | - | Elite Pharmaceuticals, Inc. to Host Conference Call to Provide Corporate Update and Discuss First Quarter 2026 Financial Results on August 15, 2025 | Northvale, New Jersey--(Newsfile Corp. - August 8, 2025) - Elite Pharmaceuticals, Inc. (OTCQB: ELTP) ("Elite" or the "Company"), a specialty pharmaceutical company developing niche generic products... ► Artikel lesen | |
| SAVARA | 2,400 | +9,09 % | Savara GAAP EPS of -$0.14 | ||
| VIRACTA THERAPEUTICS | 0,019 | -100,00 % | NSE - Viracta Therapeutics, Inc. - 25, Notification of the removal from listing and registration of matured, redeemed or retired securities | ||
| GALECTIN THERAPEUTICS | 3,620 | +13,84 % | Galectin Therapeutics Inc.: Galectin Therapeutics Reports 2024 Financial Results and Provides Business Update | NORCROSS, Ga., March 31, 2025 (GLOBE NEWSWIRE) -- Galectin Therapeutics, Inc. (NASDAQ: GALT), the leading developer of therapeutics that target galectin proteins, today reported financial results... ► Artikel lesen | |
| BIODEXA PHARMACEUTICALS | 6,900 | -1,43 % | Biodexa Pharmaceuticals PLC: ADR Ratio Change Effective | July 31, 2025 Biodexa Pharmaceuticals PLC("Biodexa" or the "Company") ADR Ratio Change Effective ADSs Outstanding Post Ratio Change Biodexa Pharmaceuticals PLC (Nasdaq: BDRX), a clinical stage biopharmaceutical... ► Artikel lesen |
LOTUS PHARMACEUTICALS INC gehört der Branche Pharma an.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu LOTUS PHARMACEUTICALS INC finden Sie auf Wallstreet Online.